Department of Molecular and Clinical Medicine Institute of Medicine Sahlgrenska AcademyUniversity of Gothenburg Sweden.
Department of Cardiology Region Västra GötalandSahlgrenska University Hospital Gothenburg Sweden.
J Am Heart Assoc. 2021 Jan 5;10(1):e017966. doi: 10.1161/JAHA.120.017966. Epub 2020 Nov 30.
Background The long-term impact of new-onset postoperative atrial fibrillation (POAF) after coronary artery bypass grafting and the benefit of early-initiated oral anticoagulation (OAC) in patients with POAF are uncertain. Methods and Results All patients who underwent coronary artery bypass grafting without preoperative atrial fibrillation in Sweden from 2007 to 2015 were included in a population-based study using data from 4 national registries: SWEDEHEART (Swedish Web System for Enhancement and Development of Evidence-based Care in Heart Disease Evaluated According to Recommended Therapies), National Patient Registry, Dispensed Drug Registry, and Cause of Death Registry. POAF was defined as any new-onset atrial fibrillation during the first 30 postoperative days. Cox regression models (adjusted for age, sex, comorbidity, and medication) were used to assess long-term outcome in patients with and without POAF, and potential associations between early-initiated OAC and outcome. In a cohort of 24 523 patients with coronary artery bypass grafting, POAF occurred in 7368 patients (30.0%), and 1770 (24.0%) of them were prescribed OAC within 30 days after surgery. During follow-up (median 4.5 years, range 0‒9 years), POAF was associated with increased risk of ischemic stroke (adjusted hazard ratio [aHR] 1.18 [95% CI, 1.05‒1.32]), any thromboembolism (ischemic stroke, transient ischemic attack, or peripheral arterial embolism) (aHR 1.16, 1.05‒1.28), heart failure hospitalization (aHR 1.35, 1.21‒1.51), and recurrent atrial fibrillation (aHR 4.16, 3.76‒4.60), but not with all-cause mortality (aHR 1.08, 0.98‒1.18). Early initiation of OAC was not associated with reduced risk of ischemic stroke or any thromboembolism but with increased risk for major bleeding (aHR 1.40, 1.08‒1.82). Conclusions POAF after coronary artery bypass grafting is associated with negative prognostic impact. The role of early OAC therapy remains unclear. Studies aiming at reducing the occurrence of POAF and its consequences are warranted.
冠状动脉旁路移植术后新发术后心房颤动(POAF)的长期影响以及 POAF 患者早期开始口服抗凝治疗(OAC)的获益尚不确定。
本研究纳入了 2007 年至 2015 年期间在瑞典接受冠状动脉旁路移植术且术前无心房颤动的所有患者,这些患者来自于 4 个全国性注册中心:瑞典心脏网(基于推荐疗法评估的心脏病循证治疗的增强和发展的瑞典网络系统)、国家患者注册中心、配药药物注册中心和死因注册中心。POAF 的定义为术后 30 天内新发的任何心房颤动。采用 Cox 回归模型(调整年龄、性别、合并症和药物因素)评估 POAF 患者和无 POAF 患者的长期预后,以及早期开始 OAC 与结局之间的潜在关联。在 24523 例接受冠状动脉旁路移植术的患者中,7368 例(30.0%)发生 POAF,其中 1770 例(24.0%)在术后 30 天内开始服用 OAC。在随访期间(中位时间为 4.5 年,范围 0-9 年),POAF 与缺血性卒中风险增加相关(校正后风险比 [aHR]1.18[95%CI,1.05-1.32])、任何血栓栓塞事件(缺血性卒中、短暂性脑缺血发作或外周动脉栓塞)(aHR 1.16,1.05-1.28)、心力衰竭住院(aHR 1.35,1.21-1.51)和复发性心房颤动(aHR 4.16,3.76-4.60)相关,但与全因死亡率(aHR 1.08,0.98-1.18)无关。早期开始 OAC 与降低缺血性卒中和任何血栓栓塞事件的风险无关,但与大出血风险增加相关(aHR 1.40,1.08-1.82)。
冠状动脉旁路移植术后新发 POAF 与不良预后相关。早期 OAC 治疗的作用尚不清楚。需要开展旨在减少 POAF 发生及其后果的研究。